All In Biotech

Drug Trial Radar · NCT07037758

A Study of Tarlatamab in Combination With AB248 in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-311)

A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Tarlatamab in Combination With AB248 in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-311)

Last checked: Nov 20, 2026Latest source record: Sep 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

380

Planned (sponsor's estimate)

Start

Sep 16, 2025

Primary completion

Mar 18, 2028

Study completion Jan 18, 2031

Sponsor

Lead sponsor
AmgenAmgen (AMGN)
Sponsor type
Industry
Collaborators
Asher Biotherapeutics, Inc.
First posted
Jun 25, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 90 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective for dose exploration and dose expansion is to evaluate the safety and tolerability of tarlatamab in combination with AB248. The primary objective for dose exploration only is to determine the recommended dose for expansion and/or maximum tolerated combination dose (MTCD) of AB248 in combination with tarlatamab.

Conditions

  • Extensive Stage Small Cell Lung Cancer

Interventions

  • TarlatamabDrug

    Administered as an IV infusion.

  • AB248Drug

    Administered either as an IV infusion followed by a flush or using a syringe pump without a flush.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants with Treatment-emergent Adverse Events (TEAEs)Time frame: Up to 2.5 years
  2. Dose Exploration: Number of Participants with Dose-limiting Toxicities (DLTs)Time frame: Up to 35 days

Locations

19 sites in 3 countries. Site status is shown where the registry gives one.

  • Banner MD Anderson Cancer Center

    Gilbert, Arizona · Terminated

  • University of Southern California, Norris Comprehensive Cancer Center

    Los Angeles, California · Recruiting

  • Moffitt Cancer Center

    Tampa, Florida · Recruiting

  • Emory University

    Atlanta, Georgia · Recruiting

  • Norton Cancer Institute - Downtown

    Louisville, Kentucky · Recruiting

  • Dana-Farber Cancer Institute

    Boston, Massachusetts · Recruiting

  • Siteman Cancer Center

    St Louis, Missouri · Recruiting

  • Memorial Sloan Kettering Cancer Center

    New York, New York · Recruiting

  • Sidney Kimmel Cancer Center

    Philadelphia, Pennsylvania · Recruiting

  • Allegheny General Hospital

    Pittsburgh, Pennsylvania · Recruiting

  • Avera Cancer Institute

    Sioux Falls, South Dakota · Recruiting

  • Baptist Cancer Center

    Memphis, Tennessee · Recruiting

  • Swedish Cancer Institute Medical Oncology

    Seattle, Washington · Recruiting

  • Chungbuk National University Hospital

    Cheongju Chungbuk, South Korea · Recruiting

  • Seoul National University Bundang Hospital

    Seongnam-si, Gyeonggi-do, South Korea · Recruiting

  • Severance Hospital Yonsei University Health System

    Seoul, South Korea · Recruiting

  • Adana Sehir Egitim ve Arastirma Hastanesi

    Adana, Turkey (Türkiye) · Recruiting

  • Hacettepe Universitesi Tip Fakultesi Hastanesi

    Ankara, Turkey (Türkiye) · Recruiting

  • Ankara Bilkent Sehir Hastanesi

    Ankara, Turkey (Türkiye) · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.